CD279 Antibody [MIH4] (FITC)

Product Specifications

Background

The MIH4 monoclonal antibody specifically reacts with human Programmed death-1 (PD-1 or CD279), a 50-55 kDA glycoprotein. It is expressed on mainly on activated B, T, and myeloid cells. Within the cytoplasmic region, PD-1 contains an Immunoreceptor tyrosine-based inhibitory motif (ITIM) and seems to regulate peripheral tolerance. The lack or mutation of CD279 is linked to autoimmune disorders.

NCBI Gene ID

5133

Swiss Prot

Q15116

Host

Mouse

Reactivity

Human

Clonality

Monoclonal

Clone

MIH4

Conjugation

FITC

Type

Primary Antibodies

Field of Research

Immunology, Apoptosis

Purification

The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.

Concentration

Batch dependent

Buffer

Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.

Modification

None

Shipping Conditions

Blue Ice

Storage Conditions

The product should be stored undiluted at 4˚ C and should be protected from prolonged exposure to light. Do not freeze.

Fragment

Mouse IgG1, kappa

Specificity

The MIH4 monoclonal antibody specifically reacts with human Programmed death-1 (PD-1 or CD279), a 50-55 kDA glycoprotein.

Symbol

PDCD1

NCBI Official Name

Programmed cell death 1

NCBI Organism

Homo sapiens

Background Reference 01

Nishimura, H., Agata, Y., Kawasaki, A., Sato, M., Imamura, S., Minato, N., ... Honjo, T. (1996) . Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4CD8) thymocytes.International immunology,8 (5), 773-780.

Background Reference 02

Salama, A. D., Chitnis, T., Imitola, J., Ansari, M. J. I., Akiba, H., Tushima, F., ... Khoury, S. J. (2003) . Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis.The Journal of experimental medicine,198 (1), 71-78.

Background Reference 03

Carreno, B. M., Collins, M. (2002) . The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.Annual review of immunology,20 (1), 29-53.